Assessment and classification of patients with myocardial injury and infarction in clinical practice

Andrew R Chapman, Philip D Adamson, Nicholas L Mills, Andrew R Chapman, Philip D Adamson, Nicholas L Mills

Abstract

Myocardial injury is common in patients without acute coronary syndrome, and international guidelines recommend patients with myocardial infarction are classified by aetiology. The universal definition differentiates patients with myocardial infarction due to plaque rupture (type 1) from those due to myocardial oxygen supply-demand imbalance (type 2) secondary to other acute illnesses. Patients with myocardial necrosis, but no symptoms or signs of myocardial ischaemia, are classified as acute or chronic myocardial injury. This classification has not been widely adopted in practice, because the diagnostic criteria for type 2 myocardial infarction encompass a wide range of presentations, and the implications of the diagnosis are uncertain. However, both myocardial injury and type 2 myocardial infarction are common, occurring in more than one-third of all hospitalised patients. These patients have poor short-term and long-term outcomes with two-thirds dead in 5 years. The classification of patients with myocardial infarction continues to evolve, and future guidelines are likely to recognise the importance of identifying coronary artery disease in type 2 myocardial infarction. Clinicians should consider whether coronary artery disease has contributed to myocardial injury, as selected patients are likely to benefit from further investigation and in these patients targeted secondary prevention has the potential to improve outcomes.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Classification proposed by the third universal definition of myocardial infarction.
Figure 2
Figure 2
Incidence of myocardial infarction and myocardial injury stratified by age in unselected consecutive hospital inpatients with myocardial necrosis. Reproduced from Shah et al.
Figure 3
Figure 3
Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Change in cardiac troponin concentration on serial measurement is used to identify patients with acute and chronic myocardial injury. The definition of change in cardiac troponin will be dependent on the assay and should be consistent with the local pathway for the assessment of patients with an isolated presentation with suspected acute coronary syndrome. CAD, coronary artery disease.
Figure 4
Figure 4
Pathway for the investigation of patients with isolated suspected acute coronary syndrome optimised for the ARCHITECTSTAT high-sensitivity cardiac troponin I assay. Reproduced from Shah et al.

References

    1. Thygesen K, Alpert JS, Jaffe AS, et al. . Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551–67. 10.1093/eurheartj/ehs184
    1. Morrow DA, Wiviott SD, White HD, et al. . Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758–64. 10.1161/CIRCULATIONAHA.108.833665
    1. Bonaca MP, Wiviott SD, Braunwald E, et al. . American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial. Circulation 2012;125:577–83. 10.1161/CIRCULATIONAHA.111.041160
    1. White HD, Reynolds HR, Carvalho AC, et al. . Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: Results from long-term follow-up of the occluded artery trial (OAT) cohort. Am Heart J 2012;163:563–71. 10.1016/j.ahj.2012.01.016
    1. Collinson PO. Type 2 myocardial infarction. Heart 2015;101:89–90. 10.1136/heartjnl-2014-306865
    1. Shah AS, McAllister DA, Mills R, et al. . Sensitive troponin assay and the classification of myocardial infarction. Am J Med 2015;128:493–501.e3. 10.1016/j.amjmed.2014.10.056
    1. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574–81. 10.1373/clinchem.2012.192716
    1. Shah ASV, Griffiths M, Lee KK, et al. . High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ 2015;350:g7873–3. 10.1136/bmj.g7873
    1. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54–61. 10.1373/clinchem.2011.165795
    1. Collinson PO, Hammerer-Lercher A, Suvisaari J, et al. . How well do laboratories adhere to recommended clinical guidelines for the management of myocardial infarction: the cardiac marker guideline uptake in Europe (CARMAGUE) study. Clin Chem 2016;62:1264–71. 10.1373/clinchem.2016.259515
    1. Mills NL, Churchhouse AMD, Lee KK, et al. . Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011;305:1210–16. 10.1001/jama.2011.338
    1. Body R, Carley S, McDowell G, et al. . Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol 2011;58:1332–9. 10.1016/j.jacc.2011.06.026
    1. Rubini-Gimenez M, Hoeller R, Reichlin T, et al. . Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. Int J Cardiol 2013;168:3896–901. 10.1016/j.ijcard.2013.06.049
    1. Neumann JT, Sörensen NA, Schwemer T, et al. . Diagnosis of myocardial infarction using a high-sensitivity troponin i 1-hour algorithm. JAMA Cardiol 2016;1:397–404. 10.1001/jamacardio.2016.0695
    1. Roffi M, Patrono C, Collet J-P, et al. . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315. 10.1093/eurheartj/ehv320
    1. Shah ASV, Anand A, Sandoval Y, et al. . High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet 2015;386:2481–8. 10.1016/S0140-6736(15)00391-8
    1. Shah ASV, Anand A, Chapman AR, et al. . Measurement of cardiac troponin for exclusion of myocardial infarction—Authors’ reply. Lancet 2016;387:2289–91. 10.1016/S0140-6736(16)30517-7
    1. Alpert JS, Thygesen KA. The Case for a Revised Definition of Myocardial Infarction—The Ongoing Conundrum of Type 2 Myocardial Infarction vs Myocardial Injury. JAMA Cardiol 2016;1:249–50. 10.1001/jamacardio.2016.0543
    1. Alpert JS, Thygesen KA, White HD, et al. . Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med 2014;127:105–8. 10.1016/j.amjmed.2013.09.031
    1. Sandoval Y, Smith SW, Thordsen SE, et al. . Supply/demand type 2 myocardial infarction: Should we be paying more attention? J Am Coll Cardiol 2014;63:2079–87. 10.1016/j.jacc.2014.02.541
    1. White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischaemia as well as necrosis? J Am Coll Cardiol 2011;57:2406–8. 10.1016/j.jacc.2011.01.029
    1. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. . Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543–9. 10.1161/01.CIR.0000028818.33488.7B
    1. Hessel MHM, Atsma DE, van der Valk EJM, et al. . Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch 2008;455:979–86. 10.1007/s00424-007-0354-8
    1. Sabatine MS, Morrow DA, de Lemos JA, et al. . Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J 2009;30:162–9. 10.1093/eurheartj/ehn504
    1. Chin CWL, Shah ASV, McAllister DA, et al. . High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 2014;35:2312–21. 10.1093/eurheartj/ehu189
    1. Thygesen K, Mair J, Giannitsis E, et al. . How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252–7. 10.1093/eurheartj/ehs154
    1. Shah AS, Newby DE, Mills NL. High sensitivity cardiac troponin in patients with chest pain. BMJ 2013;347:f4222 10.1136/bmj.f4222
    1. Melanson SE, Conrad MJ, Mosammaparast N, et al. . Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. Clin Chim Acta 2008;395:57–61. 10.1016/j.cca.2008.05.007
    1. Makam AN, Nguyen OK. Use of cardiac biomarker testing in the emergency department. JAMA Intern Med 2015;175:67–75. 10.1001/jamainternmed.2014.5830
    1. Baron T, Hambraeus K, Sundstrom J, et al. . Type 2 myocardial infarction in clinical practice. Heart 2015;101:101–6. 10.1136/heartjnl-2014-306093
    1. Javed U, Aftab W, Ambrose JA, et al. . Frequency of elevated troponin I and diagnosis of acute myocardial infarction. Am J Cardiol 2009;104:9–13. 10.1016/j.amjcard.2009.03.003
    1. El-Haddad H, Robinson E, Swett K, et al. . Prognostic implications of type 2 myocardial infarctions. World J Cardiovasc Dis 2012;2:237–41. 10.4236/wjcd.2012.24039
    1. Saaby L, Poulsen TS, Hosbond S, et al. . Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 2013;126:789–97. 10.1016/j.amjmed.2013.02.029
    1. Szymański FM, Karpiński G, Płatek AE, et al. . Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction. Kardiol Pol 2014;72:339–44. 10.5603/KP.a2013.0284
    1. Stein GY, Herscovici G, Korenfeld R, et al. . Type-II myocardial infarction--patient characteristics, management and outcomes. PLoS ONE 2014;9:e84285 10.1371/journal.pone.0084285
    1. Melberg T, Burman R, Dickstein K. The impact of the 2007 ESCACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study. Int J Cardiol 2010;139:228–33. 10.1016/j.ijcard.2008.10.021
    1. Sandoval Y, Thordsen SE, Smith SW, et al. . Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. Eur Heart J: Acute Cardiovasc Care 2014;3:317–25. 10.1016/S0735-1097(13)60235-1
    1. Smith SW, Pearce LA, Murakami MM, et al. . Diagnosis of type I versus type II myocardial infarction in emergency department patients with ischemic symptoms. Ann Emerg Med 2011;58:S211–12. 10.1016/j.annemergmed.2011.06.129
    1. Smith SW, Diercks DB, Nagurney JT, et al. . Central versus local adjudication of myocardial infarction in a cardiac biomarker trial. Am Heart J 2013;165:273–9. 10.1016/j.ahj.2012.12.012
    1. Bonaca MP, Ruff CT, Kosowsky J, et al. . Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study. Eur Heart J Acute Cardiovasc Care 2013;2:195–202. 10.1177/2048872613486249
    1. Sarkisian L, Saaby L, Poulsen TS, et al. . Clinical Characteristics and Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and Nonelevated Troponins. Am J Med 2016;129:446.e5–21. 10.1016/j.amjmed.2015.11.006
    1. Chapman AR, Shah AS, Anand A, et al. . Long term outcomes of patients with type 2 myocardial infarction and myocardial injury. Eur Heart J 2016;37(Suppl 1):987.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel